Verastem
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Verastem sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Verastem: 21 sponsored US clinical trials, 4 recruiting.
Verastem sponsors 21 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is KRAS Activating Mutation, with 3 trials.
Top-decile sponsor footprint
Verastem ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
6 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (46.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
21 total, page 1 of 1
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05375994
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270
Food Effect of VS-6766 in Healthy Adult Subjects
NCT05187169
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
NCT04620330
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
NCT02943317
Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects
NCT02651727
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
NCT02372227
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
NCT02004028
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
NCT01991938
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
NCT01951690
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
NCT01870609
Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
NCT01849744
Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
NCT01778803
A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
NCT00787033
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
NCT00666926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 7 |
| Phase 3 | 1 |
What is open in the Verastem pipeline
4 recruiting of 21 indexed (19% open); 6 completed (29%).
Phase mix: 1 late (III/IV) vs 20 early (I/II) (early-phase heavy).
Top condition: KRAS Activating Mutation (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Verastem: open-pipeline peers nationwide
Peers matched on 21 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Verastem sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 trials (± recruiting share)
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Jonsson Comprehensive Cancer Center · 19% recruiting · 321 trials
Related
What to do with this Verastem page
21 registered trials is a research-attention snapshot, not an endorsement of Verastem or any single study.
- 4 of Verastem's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- KRAS Activating Mutation is the condition Verastem studies most, compare against other sponsors active in the same condition before evaluating a specific study. See KRAS Activating Mutation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Verastem pipeline card: 21 registered trials from official public datasets.Report a data error.